Resmed (RMD, TP $4.10) - HOLD RMD reported FY08 NPAT of $113.2, up 4.7 per cent on the pcp. RMD had better-than-expected revenue growth, with sales in the EU increasing 32 per cent on pcp. However, the gross margin suffered due to an appreciating AUD vs the USD. We continue to foresee potential upside from US home diagnosis in 2H09F. In this quarter, RMD released three new machines into the US market - the S8 II, the S8 Elite and the S8 Escape. The company also entered the market with the Swift II LT mask, which had strong take-up in markets where it was released. ANALYST: Dr David Stanton, ABN AMRO
RMD Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held